5/27/2020 7:01:44 AM
Alkermes Plans To Present New Research From Its Schizophrenia Portfolio At ASCP 2020 Annual Meeting
5/20/2020 7:08:05 AM
Alkermes Says Data From Phase 3b ALPINE Study Published In Journal Of Clinical Psychiatry
5/14/2020 7:03:06 AM
Alkermes Presents New Data From Schizophrenia Portfolio At Virtual 2020 Congress Of SIRS
5/11/2020 7:03:07 AM
Alkermes Expands Several Programs To Support Uninterrupted Access To ARISTADA® And VIVITROL® During COVID-19 Crisis
4/29/2020 7:05:05 AM
Alkermes Q1 GAAP Loss Per Share $0.24 Vs Loss $0.62 Last Year
4/22/2020 7:02:06 AM
Alkermes Announces Publication Of Preclinical Data For ALKS 4230 In The Journal For ImmunoTherapy Of Cancer
3/4/2020 7:06:31 AM
Alkermes Publishes Results From Phase 3 ENLIGHTEN-1 Clinical Trial Of ALKS 3831 In Journal Of Clinical Psychiatry
2/13/2020 7:02:09 AM
Alkermes Plc Q4 Loss Per Share $0.03; Non-GAAP EPS $0.83
1/28/2020 7:01:53 AM
Alkermes Says FDA Accepts ALKS 3831 NDA For Review For Treatment Of Schizophrenia And Bipolar I Disorder
11/25/2019 7:01:14 AM
Alkermes Completes Acquisition Of Rodin Therapeutics
11/19/2019 7:01:43 AM
Alkermes Submits NDA To FDA For ALKS 3831 For Treatment Of Schizophrenia And Bipolar I Disorder